Clinical trial
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160
Study timeline
Study start (actual)2024-01-04Date precision: day
Registry last updated2026-07-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumorsunresolved
Interventions
INCB161734DRUG
CetuximabDRUG · verified · RxNorm: cetuximab
RetifanlimabDRUG · verified · RxNorm: retifanlimab
GEMNabPDRUG
mFOLFIRINOXDRUG
FOLFOXDRUG
FOLFIRIDRUG
INCA33890DRUG
Sponsors & collaborators
Incyte Corporationlead sponsor
Mapped research locations
New YorkNew York, United States2MadridSpain2MelbourneVictoria, Australia2HoustonTexas, United States1BostonMassachusetts, United States1PhiladelphiaPennsylvania, United States1BaltimoreMaryland, United States1TorontoOntario, Canada1NashvilleTennessee, United States1BarcelonaSpain1PhoenixArizona, United States1DenverColorado, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06179160 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.